A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 4 – monitoring after market approval
Conditions:
Chronic Lymphocytic Leukemia
Lymphoma, Small Lymphocytic
Sponsor: Eli Lilly and Company
trial.available_in:
БГ
Overview
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Who can participate
Inclusion Criteria:
* Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020
Exclusion Criteria:
* This is not applicable to this study
БГ